COVID-19 Resources for CRRT Treatment
CRRT is preferred treatment modality for COVID-19 patients with AKI
To continue supporting our physicians and nurses who are on the front lines of managing the influx of critically ill patients, many of whom will develop acute kidney injury or experience renal failure during this pandemic, we have consolidated support resources to help you with providing these patients Continuous Renal Replacement Therapy.
The Role of CRRT in the Fight
of patients with COVID-19 who are admitted to the ICU have AKI requiring RRT.1-3 There is some evidence that COVID-19 interferes with kidney function itself.1
is the mortality rate seen in patients with combined respiratory failure and AKI, indicating the consequences of AKI in mechanically ventilated patients is significant (independent mortality of AKI in the ICU is 30-50%).4
Go directly to more information on the following:
"Acute kidney injury (AKI) requiring acute renal replacement therapy (RRT) occurs in approximately 15% of all ICU admissions, but this rate is often increased greatly in the setting of severe respiratory failure and acute respiratory distress syndrome (ARDS)."
- American Society of Nephrology
Recommendations on the care of hospitalized patients with COVID-19 and kidney failure requiring renal replacement therapyView ASN Guidelines
"Now, more than ever, Continuous Renal Replacement Therapy is a critical therapy to be used for patients with AKI requiring renal replacement therapy and especially for those patients who are hemodynamically unstable. It has been reported in various countries that a subset of patients with COVID-19 will become severely ill, with a sepsis like syndrome and multiorgan failure, including acute kidney injury. In these critical cases, CRRT may be a life sustaining and life saving therapy."
- Mary Gellens, MD
Senior Medical Director Baxter Healthcare Corporation
In times of uncertainty, the ability to learn and be proactive makes a huge difference. Our understanding of SARS-CoV-2 prevention and treatment evolves day by day. The clinical characteristics of acute kidney injury (AKI) are heterogeneous and its incidence is reported in up to 25% of patients, some of them requiring renal replacement therapy (RRT). Therefore, preparedness is of utmost importance to maximize our capacity for the provision of RRT. Timely initiation, optimal fluid management and protocolized care with consideration for minimizing healthcare provider exposure should be carefully evaluated.
– Javier A. Neyra, MD, MSCS, FASN
Assistant Professor, Internal Medicine/Nephrology/Bone and Mineral Metabolism Director, Acute Care Nephrology & CRRT Program University of Kentucky Medical Center, Lexington, Kentucky
The current treatment of COVID-19 with AKI includes general and supportive management and kidney replacement therapy. There is no effective antiviral therapy available at present.
- The Novel Coronavirus 2019 epidemic and kidneys.
The consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup has been published. The report consists of five work groups addressing: pathophysiology and effects of treatments on the kidney; epidemiology and diagnosis; prevention and management; RRT, particularly under conditions of increased demand (surge); and the use of other forms of extracorporeal blood purification (EBP) for patients with COVID-19 with or without AKI.
-COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup
OXIRIS 3-in-1 Filter
PRISMAFLEX ST Filter Set
REGIOCIT Replacement Solution
PRISMAFLEX HF20 Filter Set
PRISMAX Training Videos
PRISMAFLEX Training Videos
BCCI Video Presentation: Principles of CRRT
BCCI WEBINAR: COVID-19 and AKI: What Has Been Learned?
BCCI WEBINAR: COVID-19: The Role of CRRT in AKI
Reimbursement Coding for CRRT and RRTView resource
Therapy Modalities, Comparisons, and ConsiderationsView resource
KDIGO Guidelines or Quick ReferenceView resource
PRISMAFLEX/PRISMAX Safety Alert Regarding Modifications to Set-upView resource
PRISMAFLEX/PRISMAX Systems Cleaning for SARS-CoV-2View resource
PRISMAFLEX Operator’s ManualView resource
PRISMAX Operator’s ManualView resource
Clinical Support Help-line
MD and PharmD on call at all times to help answer your questions and/or help you troubleshoot step-by-step.
If you need ordering or logistics support, call
888-229-0001 or online
For immediate rental needs, call customer service at:
U.S. Medical Information
For product questions or complaints, call
888-736-2543 Option 2
Center for Disease Control and Prevention
The Society of Critical Care Medicine
American Association of Critical-Care Nurses (AACN)
American Society of Nephrology (ASN)
Indications and Important Risk Information
The PRISMAFLEX and PRISMAX Systems are intended for:
PHOXILLUM and PRISMASOL Renal Replacement Solution
PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances
Important Risk Information
For more information, please see Full Prescribing Information for PRISMASOL and PHOXILLUM solutions or visit baxterpi.com.